Skip to main content

Stopping Aspirin One Month After Coronary Stenting Procedures Significantly Reduces Bleeding Complications in Heart Attack Patients


Breakthrough study led by Mount Sinai researcher could change standard-of-care guidelines to improve outcomes

Withdrawing aspirin one month after percutaneous coronary intervention (PCI) in high-risk heart patients and keeping them on ticagrelor alone safely improves outcomes and reduces major bleeding by more than half when compared to patients taking aspirin and ticagrelor combined (also known as dual antiplatelet therapy or DAPT), which is the current standard of care.

These are the results from the ULTIMATE-DAPT study announced during a late-breaking trial presentation at the American College of Cardiology Scientific Sessions on Sunday, April 7, and published in The Lancet 

Learn More

Read Abstract